Qingping Liu

Qingping Liu


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
JLJingda Li
Jingda Li
CYChengjie Yu
Chengjie Yu
RWRenjun Wang
Renjun Wang
JXJianrong Xu
Jianrong Xu
YCYan Chi
Yan Chi
QLQingping Liu
Qingping Liu

27 June 2014 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
JLJingda Li
Jingda Li
YCYan Chi
Yan Chi
SLShuqian Liu
Shuqian Liu
LWLe Wang
Le Wang
RWRenjun Wang
Renjun Wang
QLQingping Liu
Qingping Liu

1 May 2017 in Life Sciences
Verified
Journal Article
Closed access
JLJingda Li
Jingda Li
ZXZhilong Xiu
Zhilong Xiu
RWRenjun Wang
Renjun Wang
CYChengjie Yu
Chengjie Yu
YCYan Chi
Yan Chi
QLQingping Liu
Qingping Liu

1 January 2023 in Database: The Journal of Biological Databases and Curation
Verified
Journal Article
Open access
PDF file
LCLing-Ping Cen
Ling-Ping Cen
TNTsz Kin Ng
Tsz Kin Ng
JJJie Ji
Jie Ji
JLJian-Wei Lin
Jian-Wei Lin
YYYao Yao
Yao Yao
MZMingzhi Zhang
Mingzhi Zhang
The aim of the study is to establish an online database for predicting protein structures altered in ocular diseases by Alphafold2 and RoseTTAFold algorithms. Totally, 726 genes of multiple ocular diseases were collected for protein structure prediction. Both Alphafold2 and RoseTTAFold algorithms were built locally using the open-source codebases. A dataset with 48 protein structures from Protein Data Bank (PDB) was adopted for algorithm set-up validation. A website was built to match ocular genes with the corresponding predicted tertiary protein structures for each amino acid sequence. The predicted local distance difference test-Cα (pLDDT) and template modeling (TM) scores of the validation protein structure and the selected ocular genes were evaluated. Molecular dynamics and molecular docking simulations were performed to demonstrate the applications of the predicted structures. For the validation dataset, 70.8% of the predicted protein structures showed pLDDT greater than 90. Compared to the PDB structures, 100% of the AlphaFold2-predicted structures and 97.9% of the RoseTTAFold-predicted structure showed TM score greater than 0.5. Totally, 1329 amino acid sequences of 430 ocular disease-related genes have been predicted, of which 75.9% showed pLDDT greater than 70 for the wildtype sequences and 76.1% for the variant sequences. Small molecule docking and molecular dynamics simulations revealed that the predicted protein structures with higher confidence scores showed similar molecular characteristics with the structures from PDB. We have developed an ocular protein structure database (EyeProdb) for ocular disease, which is released for the public and will facilitate the biological investigations and structure-based drug development for ocular diseases. Database URL: http://eyeprodb.jsiec.org

11 January 2026 in ACS Omega
Verified
Journal Article
Open access
YWYuhang Wang
Yuhang Wang
SCShaolang Chen
Shaolang Chen
YCYingjie Cao
Yingjie Cao
XWXin Wen
Xin Wen
CFChangzhen Fu
Changzhen Fu
QLQingping Liu
Qingping Liu
Age-related macular degeneration (AMD) is a leading cause of blindness among the elderly worldwide. Neovascular AMD (nAMD) is a significant subtype of AMD, responsible for the blindness of over 90% of patients with AMD. The hallmark of nAMD is choroidal angiogenesis dysregulation, a condition that can result in severe inflammation, leakage, and bleeding, ultimately leading to a precipitous decline in visual acuity. Inhibition of the vascular endothelial growth factor (VEGF) pathway has been proven to be an effective therapeutic strategy for this disease. Intraocular injection of anti-VEGF macromolecule drugs is a clinical therapy for this disease, but it has shortcomings, such as severe side effects, high cost, long treatment cycle, and complex administration methods. Consequently, the identification of novel small-molecule drugs and the development of innovative delivery mechanisms are of paramount importance for the treatment of this condition. Chuanxiong Rhizoma (CX), a type of traditional Chinese medicine (TCM), has been employed in the treatment of vascular-related diseases. Contemporary pharmacological research has demonstrated that CX contains a substantial quantity of natural compounds that exhibit anti-VEGF activity. In this study, we employed molecular simulation docking and molecular dynamics (MD) to examine the anti-VEGFR2 effects of 10 natural compounds derived from CX. Sorafenib was selected as the reference ligand, which is a marketed VEGFR2 inhibitor for cancer treatment. As a DFG-out inhibitor, sorafenib stabilizes the inactive conformation of the kinase by binding to an allosteric site near the ATP-binding pocket. In our research, natural products exhibiting a strong binding affinity were identified using computer-simulated docking technology and detailed binding sites were predicted. The findings of the research indicate that apigenin exhibits the strongest affinity for the VEGFR2 receptor with the formation of three hydrogen bonds. The molecular docking results indicate that the CYS919 and ASP1046 amino acid residues of VEGFR2 are the primary groups that form hydrogen bonds with the ligands. Furthermore, the AutoQSAR module of Schrödinger Suite predicted apigenin to have the highest predicted pIC50 value among the ten candidate compounds, suggesting its potential for significant VEGFR2 inhibitory activity. A subsequent MD simulation revealed that the binding of apigenin to the protein was more stable, and the conformation was stronger. According to the ADMET prediction results, apigenin is characterized by low toxicity. To ascertain the capacity of apigenin to impede the proliferation of choroidal angiogenesis, the choroid sprouting assay was utilized as a methodological framework. An in vitro experiment demonstrated that apigenin can significantly inhibit the growth of choroidal vessels in a dose-dependent manner. The present study was conducted with the objective of assessing the potential of natural products in the treatment of nAMD. In addition, the study offered valuable insights for the development of new natural agents.

1 June 2014 in Atherosclerosis
Verified
Journal Article
Closed access
PDF file
YCYan Chi
Yan Chi
LWLe Wang
Le Wang
YLYuanyuan Liu
Yuanyuan Liu
YMYanhua Ma
Yanhua Ma
RWRenjun Wang
Renjun Wang
QLQingping Liu
Qingping Liu